Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.

Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications.

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests NSR reports grants and consulting fees from Bristol Myers Squibb–Celgene, Bluebird Bio, Amgen, Janssen, GlaxoSmithKline, Caribou Biosciences, and Immuneel; and personal fees from Research to Practice, Karyopharm, Takeda, Amgen, and Janssen, outside the submitted work. SKK reports grants and consulting fees from Bristol Myers Squibb–Celgene, Takeda, Abbvie, Roche, and Janssen; grants from Medimmune, Tenebio, and Carsgen; and personal fees from Oncopeptides, Beigene, and Antengene, outside the submitted work. SL reports personal fees from Celgene, Janssen, Takeda, Novartis, Bristol Myers Squibb, GlaxoSmithKline, and Amgen, outside the submitted work. TM reports personal fees from GlaxoSmithKline; and grants from Sanofi, Janssen, and Amgen, outside the submitted work. MAG reports personal fees from Abbvie, Celgene, Akcea, i3Health, Prothena, Research to Practice, Alnylym, Ambry Genetric, Amgen, Janssen, Celgene, Aurora Bio, Ionis, Karyopharm, and Sanofi; and grants from Pfizer, outside the submitted work. PH reports grants and personal fees from Bristol Myers Squibb, Takeda, Amgen, Janssen, and Legend Biotech, outside the submitted work. HL reports personal fees from Janssen, Bristol Myers Squibb–Celgene, and Seattle Genetics; and grants and personal fees from Amgen and Takeda, outside the submitted work. JLK reports grants from Abbvie; personal fees from TG Therapeutics and Incyte; and grants and personal fees from Janssen, Bristol Myers Squibb, Amgen, and Takeda, outside the submitted work. ADC reports personal fees from Bristol Myers Squibb–Celgene, Janssen, Takeda, AstraZeneca, Genentech–Roche, Oncopeptides, and Seattle Genetics; grants from Novartis; and grants and personal fees from GlaxoSmithKline, outside the submitted work. LG reports personal fees from Amgen, Takeda, Novartis, Bristol Myers Squibb, Janssen, and Sanofi, outside the submitted work. ET reports personal fees from Bristol Myers Squibb; grants and personal fees from GlaxoSmithKline, Janssen, and Sanofi; and grants, personal fees, and consulting fees from Amgen, Genesis Pharma, and Takeda, outside the submitted work. RN reports personal fees from Takeda, Amgen, Celgene, Janssen, Karyopharm, GlaxoSmithKline, and Bristol Myers Squibb, outside the submitted work. NL reports consulting fees from AbbVie, Takeda, and Omeros; and grants from Omeros and Alnylam, outside the submitted work. ME reports grants from Amgen, Bristol Myers Squibb, Janssen, Takeda, Sanofi, and GlaxoSmithKline, outside the submitted work. AB reports personal fees from BeiGene, Sanofi Genzyme, Pharmacyclics, and Karyopharm, outside the submitted work. AC reports personal fees from Bristol Myers Squibb, Karyopharm, Sanofi, Oncopeptides, Antengene, GlaxoSmithKline, Secura Bio, and Shattuck Labs; grants from Pharmacyclics; and grants and personal fees from Janssen, Celgene, Novartis Pharmaceuticals, Amgen, Seattle Genetics, and Millenium–Takeda, outside the submitted work. BL reports personal fees from Karyopharm, Bristol Myers Squibb, Janssen, and GlaxoSmithKline; grants from Cellectar; and grants and personal fees from Amgen, outside the submitted work. JR reports personal fees from Bristol Myers Squibb, Takeda, Karyopharm, Oncopeptides, AstraZeneca, Adaptive Biotechnologies, Janssen, Secura Bio, and Sanofi, outside the submitted work. JSM reports personal fees from Amgen, Bristol Myers Squibb, Celgene, Janssen, Merck, Novartis, Takeda, Sanofi, Roche, GlaxoSmithKline, Abbvie, Karyopharm, and SecuraBio, outside the submitted work. KCA reports personal fees from Amgen, Pfizer, Janssen, AstraZeneca, Precision Biosciences, Windmill, Mana, Starton, Raqia, Oncopeptides, and C4 Therapeutics, outside the submitted work. PLM reports personal fees from BlueBird Biotech, Bristol Myers Squibb, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Takeda, and Medscape; grants from Celgene; and non-financial support from Sanofi, outside the submitted work. NCM reports personal fees from Bristol Myers Squibb, Oncopeptides, Janssen, Amgen, Novartis, Takeda, Abbvie, and C4 Therapeutics, outside the submitted work. All other authors declare no competing interests.